Impact of Germline BRCA1/2 Mutations on Clinical Outcomes in Metastatic Triple-Negative Breast Cancer Patients Treated with Sacituzumab Govitecan-An International CEBCC Study from Poland, the Czech Republic and Slovakia.

Pacholczak-Madej R, Püsküllüoğlu M, Polakiewicz-Gilowska A, Pieniążek M, Kolářová I, Malejčíková M, Rušinová L, Holánek M, Soumarová R, Winsko-Szczęsnowicz K, Żubrowska J, Konieczna A, Młodzińska A, Krejčí D, Danielewicz I, Szymanik-Resko M, Ciszewski T, Lisik-Habib M, Pękala A, Študentová H, Šustr J, Czartoryska-Arłukowicz B, Łacko A, Smok-Kalwat J, Jarząb M, Bielčiková Z, Kubeczko M

Open source

DOI: 10.32604/or.2026.076384
Published: 2026
Container: Oncology research
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.32604/or.2026.076384,
  title = {Impact of Germline BRCA1/2 Mutations on Clinical Outcomes in Metastatic Triple-Negative Breast Cancer Patients Treated with Sacituzumab Govitecan-An International CEBCC Study from Poland, the Czech Republic and Slovakia.},
  author = {Pacholczak-Madej R and Püsküllüoğlu M and Polakiewicz-Gilowska A and Pieniążek M and Kolářová I and Malejčíková M and Rušinová L and Holánek M and Soumarová R and Winsko-Szczęsnowicz K and Żubrowska J and Konieczna A and Młodzińska A and Krejčí D and Danielewicz I and Szymanik-Resko M and Ciszewski T and Lisik-Habib M and Pękala A and Študentová H and Šustr J and Czartoryska-Arłukowicz B and Łacko A and Smok-Kalwat J and Jarząb M and Bielčiková Z and Kubeczko M},
  year = {2026},
  journal = {Oncology research},
  doi = {10.32604/or.2026.076384},
  url = {https://doi.org/10.32604/or.2026.076384}
}

RIS

TY  - JOUR
TI  - Impact of Germline BRCA1/2 Mutations on Clinical Outcomes in Metastatic Triple-Negative Breast Cancer Patients Treated with Sacituzumab Govitecan-An International CEBCC Study from Poland, the Czech Republic and Slovakia.
AU  - Pacholczak-Madej R
AU  - Püsküllüoğlu M
AU  - Polakiewicz-Gilowska A
AU  - Pieniążek M
AU  - Kolářová I
AU  - Malejčíková M
AU  - Rušinová L
AU  - Holánek M
AU  - Soumarová R
AU  - Winsko-Szczęsnowicz K
AU  - Żubrowska J
AU  - Konieczna A
AU  - Młodzińska A
AU  - Krejčí D
AU  - Danielewicz I
AU  - Szymanik-Resko M
AU  - Ciszewski T
AU  - Lisik-Habib M
AU  - Pękala A
AU  - Študentová H
AU  - Šustr J
AU  - Czartoryska-Arłukowicz B
AU  - Łacko A
AU  - Smok-Kalwat J
AU  - Jarząb M
AU  - Bielčiková Z
AU  - Kubeczko M
PY  - 2026
JO  - Oncology research
DO  - 10.32604/or.2026.076384
UR  - https://doi.org/10.32604/or.2026.076384
ER  -

APA

R, P., M, P., A, P., M, P., I, K., M, M., L, R., M, H., R, S., K, W., J, Ż., A, K., A, M., D, K., I, D., M, S., T, C., M, L., A, P., H, Š., J, Š., B, C., A, Ł., J, S., M, J., Z, B., & M, K. (2026). Impact of Germline BRCA1/2 Mutations on Clinical Outcomes in Metastatic Triple-Negative Breast Cancer Patients Treated with Sacituzumab Govitecan-An International CEBCC Study from Poland, the Czech Republic and Slovakia.. Oncology research. https://doi.org/10.32604/or.2026.076384

Source records

pubmed · retrieved 2026-09-25T14:30:27.738Z